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CD4+ T cells have been reported to suppress immu-
nity against cancer in certain animal models. In this
study, we investigated the role of CD4+ T cells in the
anti-tumor immune response when interleukin-12-
producing melanoma cells are inoculated in mice.
We found that interleukin-12-transfected B16 mela-
noma showed retarded tumor growth in syngeneic
mice; however, all the mice developed tumors even-
tually. In vivo depletion of CD4+ T cells led to com-
plete regression of B16/interleukin-12 tumors in 12
of 20 mice (60%). Immunohistochemical analyses
revealed that a number of CD8+ T cells accumulated
in close proximity to the B16/interleukin-12 tumors
in the CD4+ T cell-depleted mice, whereas CD8+ T
cells were only scarcely observed at the periphery of
the tumors in control immunocompetent mice.
Furthermore, 10 of 20 mice treated with both B16/
interleukin-12 inoculation and CD4+ T cell depletion
exhibited vitiligo-like coat color alteration. B16/
interleukin-12 tumors completely regressed in all the
mice with vitiligo. Histologic examination showed
that CD8+ lymphocytes accumulated around the hair
bulbs of mice with vitiligo, but not in those without
vitiligo. These results suggest that CD4+ T cells have
an inhibitory effect on tumor rejection by suppres-
sing cytotoxic CD8+ T cells in this melanoma load-
ing model with local interleukin-12 secretion. To
investigate the mechanism of enhanced anti-tumor
effects by CD4+ T cell depletion, we examined the T
helper type 1/2 cytokine pro®le in the tumor drain-
ing lymph nodes of B16/interleukin-12-bearing mice
with or without CD4+ T cell depletion using the
reverse transcription±polymerase chain reaction
method. We found that CD4+ T cell depletion elimi-
nated T helper type 2 cells and resulted in a T helper
type 1-dominant cytokine pro®le in tumor draining
lymph nodes. We emphasize that this T helper type
1-dominant cytokine pro®le may generate further
activated CD8+ T cells against B16 melanoma cells,
lead B16/interleukin-12 to regress, and result in the
destruction of the melanocytes in hair bulbs due to
cross-antigenicity between both cell types. This
mouse model not only demonstrates the depletion of
CD4+ T cells as a useful strategy for cancer gene
therapy with interleukin-12 but also provides a
model for human melanoma-associated vitiligo. Key
words: CD8-positive T lymphocyte/cytokine/gene therapy/
Th1/Th2. J Invest Dermatol 115:1059±1064, 2000
T
here has been an accumulation of evidence showing
that CD4+ T cells suppress immune response against
cancer in animal models. North et al showed that
advanced growth of certain tumors in mice led to the
generation of CD4+ T cells capable, on passive
transfer, of suppressing adoptive T cell mediated tumor regression
in recipient mice (North and Burssuker, 1984; North and Dye,
1985; Awwad and North, 1990). A series of studies has
demonstrated that preferential elimination of CD4+ T cells from
mice with advanced tumors by whole-body g-irradiation (North,
1986), by injection of cytotoxic drugs (Awwad and North, 1988a;
North and Awwad, 1990), or by treatment with anti-CD4
monoclonal antibodies (Awwad and North, 1988b) can result in
an augmented level of immunity against tumor cells. These effects
are believed to be due to the inhibition of CD8+ T cell response by
CD4+ T cells. It has also been shown that CD4+ T cells suppress
CD8+ T cells in contact hypersensitivity response (Xu et al, 1996).
It is thus possible that CD4+ T cells prevent CD8+ T cells from
actively responding to their target cells.
Recently, gene therapy against cancer has received much
attention, and a variety of studies on gene therapy as a treatment
for cancer have been conducted (Tepper and Mule, 1994).
Introduction of cytokine genes such as interleukin (IL) ±2
(Toloza et al, 1996; Schneeberger et al, 1999), IL-4 (Golumbek
et al, 1991), and granulocyte-macrophage colony-stimulating factor
(GM-CSF) (Armstrong et al, 1996), into tumor cells has been
shown to bene®t host immune defense against cytokine-producing
tumor transplantation. Locally secreted cytokines thus attract
migration of immunoregulatory cells, which subsequently destroy
inoculated tumor cells. IL-12 is a disul®de-linked heterodimeric
cytokine that plays a central part in the generation of T helper type
1 (Th1) cells, which are required for cell-mediated immune
response (Brunda, 1994; Trinchieri, 1994). IL-12 exerts a variety of
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biologic effects on natural killer cells and T cells in vitro. IL-12
induces interferon (IFN) -g production by natural killer cells and T
cells, and enhances cytotoxicity of these cells (Brunda, 1994;
Trinchieri, 1994). Exogenous administration of IL-12 in vivo has
exhibited marked anti-tumor and anti-metastatic activity in murine
tumor models (Brunda et al, 1993). As IL-12 has a potent anti-
tumor activity, this particular cytokine seems to be one of the most
promising cytokines for cancer gene therapy. We investigated the
anti-tumor effect of locally secreted IL-12 against B16 melanoma
cells, modulating immunoregulatory mechanisms by depleting
CD4+ T cells. We found that the in vivo depletion of CD4+ T cells
made IL-12-producing B16 melanoma cells regress, upregulating
CD8+ T cell in®ltration.
Another interesting ®nding of this study was that 83% of CD4+
T cell-depleted mice that rejected IL-12-secreting B16 melanoma
cells showed vitiligo-like coat color alteration. Melanoma-asso-
ciated vitiligo is known to be a good prognostic sign in metastatic
melanoma patients (Nordlund et al, 1983; Bystryn et al, 1987). We
also discuss the mechanism of vitiligo-like coat color alteration in
our mouse model.
MATERIALS AND METHODS
Expression vector and transfection of tumor cells The cDNA
encoding the p35 and p40 subunits of mouse IL-12 were kindly provided
by Dr. Maurice K. Gately (Hoffmann-La Roche, Nutley, NJ). These
cDNA were subcloned in the appropriate orientation into the plasmid
expression vector pCEXV3 (Okayama and Berg, 1983). DNA fragments
encoding the p35 and p40 subunits were cloned into the SmaI site of
pCEXV3 and named pCEXV3/p35 and pCEXV3/p40, respectively.
Transfection was performed by standard calcium phosphate precipitation
(Sambrook et al, 1982). For drug selection, pSV2neo was cotransfected
with these vectors. Brie¯y, 1.8 3 105 tumor cells were plated in 60 mm
dishes 1 d before transfection. Nine milligrams of puri®ed pCEXV3 (as a
control) or 7 mg of pCEXV3/p35 and 7 mg of pCEXV3/p40 were
cotransfected with 1 mg of puri®ed pSV2neo (Southern and Berg, 1982).
The transfectants were then cloned using Geneticin (®nal concentration,
1.5 mg per ml, Sigma, St Louis, MO).
IL-12 assay To assess IL-12 levels, parental or IL-12 gene-transfected
tumor cells (3.0 3 105) were cultured on six-well plates with 1.5 ml of
minimal essential medium supplemented with 10% heat inactivated fetal
bovine serum, and the supernatants were collected after 24 h. IL-12 activity
was measured by lymphoblast proliferation assay as described (Gately and
Chizzonite, 1992). Brie¯y, human peripheral blood mononuclear cells
were isolated by Ficoll-Hypaque gradient centrifugation, and incubated
with phytohemagglutinin-P (PHA; Difco, Detroit, MI, 10 mg per ml) for
48 h and subsequently with human recombinant IL-2 (50 IU per ml) for
24 h. PHA blasts (2 3 104) were incubated with 50 ml of sample
supernatants or recombinant mouse IL-12 (provided by Hayashibara
Biochemical Laboratories, Okayama, Japan) as a reference standard for 24 h.
Then, the cells were pulsed with 1 mCi of [3H]thymidine and cultured for
6 h, and harvested on to glass ®ber ®lter papers. [3H]thymidine
incorporation was measured with a liquid scintillation counter. IL-12
activity of the sample supernatants was calculated according to the reference
of the standard IL-12. Simultaneous IL-12 enzyme-linked immunosorbent
assay assay (mouse IL-12 p70 enzyme-linked immunosorbent assay kit;
BioSource International, Camarillo, CA) con®rmed the results.
Tumor cell lines and animal studies B16 melanoma cell line of
C57BL/6 mouse origin was maintained in Eagle's minimal essential
medium supplemented with 5% heat-inactivated fetal bovine serum at
37°C in a 5% CO2/air humidi®ed atmosphere. Speci®c pathogen-free
C57BL/6 mice (6±8 wk old females) were purchased from CLEA Japan
(Tokyo, Japan). All animals were maintained in microisolator cages and
exposed to a 12 h light/12 h dark cycle, with standard feed and water
provided ad libitum. All animal experiments were conducted according to
the ``Guidelines for Animal Experimentation at Kobe University School of
Medicine''. Cultured tumor cells were trypsinized and washed twice with
phosphate-buffered saline, and 106 cells in 0.1 ml phosphate-buffered saline
per mouse were injected subcutaneously into the right ¯ank of C57BL/6
mice. Each experimental group consisted of ®ve to 10 mice. The tumor
size was measured in millimeters using calipers every 2±3 d. The longest
length (a) and its perpendicular width (b) were measured, and tumor size
was reported as a ¢b. Statistical evaluation of the data were performed using
Student's t test.
Antibody treatments in vivo To deplete CD8+ T cells and CD4+ T
cells in vivo, we administered intraperitoneally rat monoclonal antibody
2.43 [anti-CD8; IgG2b, American Type Culture Collection (ATCC),
Rockville, MD] and GK1.5 (anti-CD4; IgG2b, ATCC). The monoclonal
antibody preparation (0.2 ml) of ascites ¯uids was injected intraperitoneally
on days ±3, ±2, ±1, 13, and every 7 d thereafter. Under these conditions,
antibody treatment depleted > 95% of the CD8+ T cell and CD4+ T cell
population in the spleen, throughout the experiments. Depletion of natural
killer cells was performed using polyclonal anti-asialo GM1 antibody
(Wako Fine Chemicals, Osaka, Japan). A total of 50 ml of anti-asialo GM1
antibody diluted with 150 ml of phosphate-buffered saline was injected
intraperitoneally on day ± 1 and every 5 d thereafter. Depletion of natural
killer cells was con®rmed by 4 h 51Cr-release assays with YAC-1 cells as
target cells and spleen cells as effector cells.
Immunoblotting analysis B16 melanoma cells were lyzed by 1.0%
NP-40 lysis buffer, separated in 7% sodium dodecyl sulfate±polyacrylamide
gel by electrophoresis, and transferred on to nitrocellulose membrane. The
membrane was blocked with 5% skim milk at 4°C overnight and incubated
with sample mouse sera for 1 h at room temperature and then incubated
with horseradish peroxidase-conjugated sheep anti-mouse immuno-
globulins (Amersham International, Buckinghamshire, U.K.). The
binding secondary antibody was visualized by Hyper®lm-ECL system
(Amersham International).
Histologic analysis For histologic examination, tissues at the tumor site
and skins were collected appropriately. Hematoxylin±eosin stain was done
with a routine method. Immunohistochemical analysis was performed with
the avidin±biotin complex method using a Vectastain ABC Kit (Vector
Laboratories, Burlingame, CA). Six millimeter cryostat sections were
immunostained with rat anti-mouse monoclonal antibodies against CD4+
T cell (GK1.5), CD8+ T cell (2.43), macrophages (F4/80, ATCC), and
rabbit polyclonal antibody against natural killer cells (anti-asialo GM1,
Wako). Sections were preincubated with bovine serum, incubated with
optimal dilutions of primary antibodies and followed by biotinylated
secondary antibodies, rabbit anti-rat IgG[H+ L] (Vector Laboratories) for
rat primary antibodies, and swine anti-rabbit immunoglobulins (DAKO A/
S, Glostrup, Denmark) for anti-asialo GM1. Sections were incubated with
0.03% H2O2 in methanol for 15 min, and then with horseradish
peroxidase-conjugated avidin for 45 min. Adsorbed peroxidase was
visualized by incubating with 0.05% 3.3¢-diaminobenzidine (Dojindo
Laboratories, Kumamoto, Japan) for 1±2 min, and counterstained with
methylgreen.
RNA extraction from tumor-draining lymph nodes (TDLN). IL-12
gene-transfected tumor cells (1 3 106) in phosphate-buffered saline were
inoculated subcutaneously in the thigh of syngeneic mice. After 7 and 21 d,
Figure 1. IL-12-transfected B16 melanoma showed retarded tumor
growth in syngeneic mice. C57/BL6 mice were challenged with B16
parental melanoma (B16/P), control vector-transfected cell line (B16/C) or
clones of B16 melanoma transduced with IL-12 (B16/IL-12 no. 1, B16/IL-
12 no. 2). Mice were subcutaneously injected with 106 cells in the right
¯ank on day 0. Tumor size was measured as the product of the longest
diameter 3 perpendicular diameter. Data are presented as mean values of
tumor size of ®ve mice per group. Error bars represent SD. m, B16/P; r,
B16/C; d, B16/IL-12 no. 1; s, B16/IL-12 no. 2. *p < 0.01, **p < 0.01
(Student's t test).
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TDLN were resected. Total RNA was isolated using acid-guanidinium
thiocyanate±phenol±chloroform (Chomczynski and Sacchi, 1987) from
TDLN.
Reverse transcriptase±polymerase chain reaction (reverse
transcription±PCR) Complementary DNA (cDNA) was synthesized
from 5 mg of RNA by extension with oligo dT in a 20 ml reaction volume
containing reverse transcriptase reaction buffer (pH 8.3), 0.01 M
dithiothreitol, 0.5 mM deoxynucleotide phosphate, and 200 U of
Superscript II (Gibco BRL, Grand Island, NY). The mixture was
incubated at 37°C for 1 h and then at 70°C for 15 min.
The presence of cDNA for IL-2, IFN-g, IL-4, and IL-10 was detected by
PCR ampli®cation, using the Quantitative PCR# Detection Kit (Mouse
TH1/TH2 Swith Cytokine, BioSource International, Inc.) according to
the manufacturer's instructions. PCR was performed using a Perkin Elmer
Cetus Gene Amp PCR system 9600 (Norwalk, CT) in a 50 ml reaction
volume using Ampli-Taq (Perkin Elmer). Nonspeci®c priming and
oligomerization was minimized using hot-start PCR. A sample of each
reaction (15 ml) was analyzed in 2% agarose gel and visualized by ethidium-
bromide ¯uorescence staining. A PCR marker (Promega, Madison, WI)
was used as a molecular-weight marker to estimate the size of fragments.
RESULTS
IL-12 production by transfectants A series of transduced
clones was picked up and the IL-12 activity in their culture
supernatants was determined. Two clones were selected as having a
high level of IL-12-producing clones. The selected clones (B16/IL-
12 no. 1 and no. 2) produced 45 and 40 ng per ml of IL-12 per 106
cells per 24 h, respectively (data not shown). Neither parental
tumor cells (B16/P) nor tumor cells transduced with the pCEXV3
vector (B16/C) produced detectable IL-12.
Tumor growth of IL-12-transfected B16 melanoma cells in
syngeneic mice To investigate the effects of locally secreted IL-
12 on tumor growth, 106 cells of B16/IL-12 no. 1, B16/IL-12 no.
2, B16/C and B16/P were injected into the right ¯ank of syngeneic
mice. B16/P and B16/C exhibited almost the same degree of
tumor growth. On the other hand, B16/IL-12 no. 1 and no. 2
exhibited signi®cant retardation of tumor growth as compared with
B16/P or B16/C (Fig 1). As B16/IL-12 no. 1 exhibited a more
pronounced retardation of tumor growth than B16/IL-12 no. 2
did, B16/IL-12 no. 1 was used in the following experiments
(hereafter referred to as B16/IL-12).
Tumor growth of B16/IL-12 in natural killer, CD8+ T or
CD4+ T cell-depleted mice In order to characterize the cells
responsible for the inhibition of tumor growth, tumor-bearing
hosts were depleted in vivo in selected effector cell populations.
Depletion of CD8+ T cells by anti CD8 monoclonal antibodies as
well as natural killer cells by anti-asialo GM1 sera accelerated the
tumor growth of B16/IL-12, and resulted in a statistically
signi®cant difference (p < 0.05, Student's t test) from the
untreated group (Fig 2). These results suggest that the retarded
growth of IL-12-producing B16 melanoma cells is mediated
through natural killer cells as well as CD8+ T cells. On the other
hand, depletion of CD4+ T cells inhibited the tumor growth of
B16/IL-12 in all of the mice examined (Fig 2) and resulted in
complete regression in 12 of 20 mice (60%) at 60 d after tumor
injection. In the remaining 40% of mice with CD4+ T cell
depletion, the tumor growth of B16/IL-12 was signi®cantly slower
than that of the untreated group (data not shown).
Coat color alteration in completely regressed mice by CD4+
T cell depletion Twelve of the 20 mice in which CD4+ T cells
were depleted and that were injected with B16/IL-12 cells
exhibited vitiligo-like coat color alteration beginning
approximately 30±50 d after tumor inoculation (Fig 3). A various
degree of depigmentation was observed, and a prominent one
exhibited white color alteration almost entirely. The relationship
between vitiligo and tumor incidence at 60 d after tumor
inoculation is summarized in Table I. All 10 mice with coat
color alteration completely rejected B16/IL-12 tumors, whereas
only two of the 10 mice without vitiligo-like change showed
tumor rejection (p < 0.001, c2-test). In other words, 83% of the
mice that rejected the tumor showed vitiligo. Mice with CD4+ T
cell depletion and B16/P inoculation did not show this vitiligo-like
coat color change.
Immunoblotting analysis To examine whether the mice with
vitiligo raised antibodies against B16 melanoma cells,
immunoblotting analysis was performed using the sera from
untreated control mice and CD4+ T depleted mice with coat
color alteration. No signi®cant differences were seen between
control and coat-color-altered mice (data not shown).
Histologic analysis To investigate further the cellular
mechanism of the augmentation of the anti-tumor effect of B16/
IL-12 by CD4+ T depletion, immunohistologic analyses were
performed. Immunohistochemical stainings of tumor specimens 7 d
after tumor inoculation showed that a number of CD8+ T cells
accumulated in close proximity to B16/IL-12 tumors in CD4+ T
cell-depleted mice, whereas only a few CD8+ T cells were
observed at the periphery of B16/IL-12 tumors in untreated
control mice (Figs 4a, b). Strong in®ltrations of asialo GM1+ cells
and macrophages were seen at the center and periphery of B16/IL-
12 tumors in CD4+ T cell-depleted mice, but no difference in the
degree of cell in®ltration was found between mice with and
without CD4+ T cell depletion (data not shown).
To examine the histologic changes at the follicles with coat color
alteration, skin tissues were resected at 60 d after tumor inoculation.
Hematoxylin±eosin staining in the specimens of skin with hair
depigmentation showed that mononuclear cells accumulated
around the lower portion of follicles, especially in hair bulbs, but
scarcely around the upper portion (Fig 5a). Specimens of the skin
Figure 2. CD4+ T cell depletion led to regression of B16 melanoma
transduced with IL-12. B16 melanoma transduced with IL-12 (B16/IL-
12) were challenged in C57/BL6 mice depleted of natural killer cells,
CD8+ T cells, and CD4+ T cells. Depletion of natural killer cells, CD8+ T
cells, and CD4+ T cells was performed as described in Materials and Methods.
Mice were subcutaneously injected with 106 cells in the right ¯ank on day
0. Tumor measurements were performed as described in Fig 1 and in
Materials and Methods. Data are presented as mean values of tumor size of six
to eight mice per group. Error bars represent SD. m, B16/P in C57/BL6
mice; d, B16/IL-12 in C57/BL6 mice; h, B16/IL-12 in natural killer cell-
depleted C57/BL6 mice; n, B16/IL-12 in CD8+ T cell-depleted C57/
BL6 mice; ,, B16/IL-12 in CD4+ T cell-depleted C57/BL6 mice.
*p < 0.05, **p < 0.05, ***p < 0.01 (Student's t test).
Table I. Correlation between coat color alternation and
tumor incidence at 60 d after tumor injection
CD4-depleted mice (n = 20) Tumor (±) Tumor (+)
Coat color alternation (±) 2 8
Coat color alternation (+) 10 0
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without coat color change did not show the follicular in®ltrates
(Fig 5b). Immunohistochemical analysis revealed that most of the
in®ltrating cells around the lower follicles and hair bulbs were
CD8+ cells (Fig 5c).
Th1/Th2 cytokine pro®le in TDLN To investigate the
mechanism of enhanced anti-tumor effects by CD4+ T cell
depletion, we examined the Th1/Th2 cytokine pro®le in the
tumor draining lymph nodes (TDLN) of mice subcutaneously
injected with B16/IL-12 cells, with or without CD4+ T cell
depletion using the reverse transcription±PCR method.
Representative results of reverse transcription±PCR for TDLN
on the seventh and 21st days after tumor injection are shown in
Fig 6. The mRNA of both Th1 cytokine (IFN-g, IL-2) and Th2
cytokine (IL-4, IL-10) were detected in mice without CD4+ T cell
depletion. On the other hand, CD4+ T cell depletion in vivo clearly
abrogated the expression of Th2 cytokines in the TDLN, whereas
Th1 cytokines were stable.
DISCUSSION
T cell-mediated immune response to malignant cells is of critical
importance in host defense against cancer; however, it is still
controversial whether CD4+ T cells play a bene®cial role in anti-
tumor immunity or not. CD4+ T cells stimulate B cells to produce
immunoglobulins that will recognize the surface antigens of tumor
Figure 4. Strong accumulation of CD8+ T
cells in B16/IL-12 tumors was induced by
CD4+ T cell depletion. Immunohistochemical
staining with anti-CD8 antibodies of B16/IL-12
tumors 7 d after tumor injection. (a) Staining of
B16/IL-12 in mice undepleted of CD4+ T cells,
showing a few CD8+ T cells at the periphery of
the tumor. (b) Staining of B16/IL-12 in mice de-
pleted of CD4+ T cells, showing strong accumula-
tion of CD8+ T cells (arrows) in close vicinity to
B16/IL-12. Scale bar: 100 mm.
Figure 5. CD8+ T lymphocytes accumulated
around the lower portion of follicles in mice
with coat color alteration. (a) Hematoxylin±eo-
sin staining of follicles in mice with coat color al-
teration, showing that lymphocytes (arrows)
accumulate around the lower portion of follicles,
but only scarcely around the upper portion. (b)
Hematoxylin±eosin staining of follicles in normal
mice, showing no lymphocytes around the folli-
cles. (c) Immunohistochemical staining with anti-
CD8 antibodies of follicles in mice with coat col-
or alteration, showing that most of the in®ltrating
cells around the lower follicles were CD8+ T cells
(arrows). Scale bar: 50 mm.
Figure 3. Alteration of coat color in CD4+ T cell-depleted C57BL/6
mice at 60 d after B16/IL-12 injection. Coat color alteration began at
30±50 d after tumor injection and thereafter increased gradually. Two
representative mice showing coat color alteration are presented. B16/IL-12
tumors were subcutaneously injected into the right ¯ank of mice. Note that
depigmentation is observed not only in the tumor inoculation site, but also
in almost the entire body.
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cells (Singer and Hodes, 1983), thereby destroying the tumor cells.
Furthermore, CD4+ T cells produce various cytokines, such as
IFN-g and tumor necrosis factor-a, that possess anti-tumor activity
(Helson et al, 1975; Asher et al, 1987; De Graaf et al, 1988; Zoller
et al, 1988). CD4+ T cells have thus been believed to play a
bene®cial role in the mechanisms of anti-tumor immunity. On the
other hand, several studies have revealed that when excess IL-2 or
IL-12 is present in the vicinity of a tumor, CD4+ T cells show an
inhibitory effect on anti-tumor immunity. Rakhmilevich and
North (1994) described that in vivo depletion of CD4+ T cells
resulted in an augmentation of the effect of anti-tumor therapy
with recombinant IL-2. A similar observation in which an anti-
tumor effect was augmented by in vivo CD4+ T cell depletion has
been described in studies using C-26 colon carcinoma transduced
with IL-12 genes (Martinotti et al, 1995) and B16 melanoma cells
transduced with IL-2 genes (Hara et al, 1995a). This evidence
indicates that CD4+ T cells act as an immunosuppressive agent in
anti-tumor immunity according to circumstances.
In this study, we showed that in vivo depletion of CD4+ T cells
enhanced the anti-tumor effect of IL-12-transfected B16 melanoma
(B16/IL-12) cells, and that this enhancement was possibly mediated
through the accumulated CD8+ T cells in the vicinity of the tumor.
Th1 cytokines, such as IL-2 and IFN-g, are believed to be
responsible for the generation of cytotoxic T lymphocytes during
anti-tumor immune response (Lee et al, 1995) as well as effector T
lymphocytes in the delayed-type hypersensitivity response (Cher
and Mosmann, 1987). In turn, Th2-type cytokines, such as IL-4
and IL-10, are known to inhibit delayed-type hypersensitivity and
cell-mediated immunity (Powrie et al, 1993). The immune
response is thus regulated by the Th1/Th2 cytokine balance
(Mosmann and Coffman, 1989; Mosmann and Sad, 1996). We
therefore hypothesized that depletion of CD4+ T cells may result in
elimination of Th2 cells (although Th1 cells are also abrogated) and
induce further activated CD8+ T cells. To prove this hypothesis,
we investigated the Th1/Th2 cytokine pro®le in TDLN of B16/
IL-12-bearing mice with or without CD4+ T cell depletion using
the reverse transcription±PCR method. As shown in Fig 6, Th2
cytokine mRNA (IL-4 and IL-10) preferentially disappeared in
mice depleted of CD4+ T cells, whereas Th1 cytokine mRNA (IL-
2 and IFN-g) were stably expressed. This indicates that the Th1/
Th2 cytokine balance was dominantly shifted to Th1 in the
draining lymph nodes. Thereby, CD8+ cytotoxic T lymphocytes
would be strongly activated by Th1 cytokines. Interestingly, Th1
cells do not seem to be required for the activation of anti-tumor
immunity in our model because CD4+ T cell depletion abolishes
both Th1 and Th2 cells.
On the contrary, CD4+ T cells have been shown to play an
important part in B16 melanoma cell rejection in a tyrosinase-
related protein-1 (TRP-1) gene vaccination study (Overwijk et al,
1999). In this particular model, anti-75 kDa protein antibodies were
generated by the vaccination. This evidence suggests that CD4+ T
cells can stimulate anti-melanoma immunity through inducing
antibody production. These diverse roles of the CD4+ T cells may
be attributed to the different experimental conditions between the
studies, that is, the IL-12-predominant environment in our study
versus gene gun-mediated plasmid vaccination, which might
activate the Th2 cytokine pro®le (Petmer et al, 1996; Feltquate
et al, 1997). Based on this evidence, we strongly suggest that CD4+
T cells play at least two distinct roles in anti-melanoma immunity:
one is an indispensable role for producing antibodies against
tumors, and the other is an inhibitory role in the activation of
CD8+ cytotoxic T lymphocytes and their in®ltration to the tumor,
where Th2 cytokines produced by CD4+ T cells are probably
responsible for the counteraction.
Another noteworthy point in this study is the induction of
vitiligo-like coat color alteration in CD4+ T cell-depleted mice
bearing B16/IL-12. In humans, the relationship between vitiligo
and melanoma has been extensively discussed. The spontaneous
appearance of vitiligo has been associated with an improved
prognosis in metastatic melanoma patients (Bystryn et al, 1987;
Nordlund et al, 1983). The mechanisms related to the development
of ``melanoma-associated vitiligo'' have not been completely
clari®ed. The destruction of melanocytes by humoral immunity
seems to be one possible mechanism. Patients with melanoma may
develop antibodies to antigens of melanoma cells (Donaldson et al,
1974; Bystryn and Naughton, 1984). It has been shown that sera
from patients with vitiligo or melanoma-associated vitiligo contain
antibodies against tyrosinase (Fishman et al, 1997), TRP-1 (Kemp
et al, 1998) and TRP-2 (Okamoto et al, 1998). These melanogenic
enzymes are highly expressed in both melanoma cells and normal
melanocytes. The antibodies to the melanoma cells will therefore
react with normal melanocytes, thereby causing melanoma-
associated vitiligo in these patients. It has been proved that the
sera of vitiligo patients without melanoma destroy human
melanocytes in vitro by complement-mediated damage and anti-
body-dependent cellular cytotoxicity (Norris et al, 1988). In this
study, immunoblotting analysis revealed that there was no
difference in the serum levels of antibodies against B16 melanoma
cells between altered-coat-color mice and untreated control mice.
This ®nding indicates that vitiligo-like depigmentation in this study
was not caused by humoral immunity.
T cell-mediated destruction of melanocytes seems to be another
mechanism of melanoma-associated vitiligo. There is clear evidence
that supports the idea that melanoma-associated vitiligo is mediated
through CD8+ cytotoxic T lymphocytes in humans. In patients with
melanoma who were treated with IL-2 and tumor-in®ltrating
lymphocytes, vitiligo has been frequently observed (Kawakami and
Rosenberg, 1997). These cytotoxic T lymphocytes are known to
react with melanoma-associated antigens such as tyrosinase, TRP-1,
TRP-2, gp100, and MART-1. These antigens are also expressed in
normal melanocytes, which may be easily destroyed by the cytotoxic
T lymphocytes speci®c to these antigens. Histologic examination in
this study showed that CD8+ T cells accumulated around the hair
bulbs in altered-coat-color mouse skin, but not in those of the
untreated mice, suggesting that CD8+ cytotoxic T lymphocytes
sensitized to B16 melanoma antigens destroyed normal melanocytes
in the hair bulbs as well. These results reveal that cellular immunity
plays a more important part in the formation of vitiligo-like coat color
alteration than humoral immunity in our model.
Bystryn (1989) has even suggested that vitiligo may be regarded
as ``an experiment of nature that accomplishes the goal of
melanoma immunotherapy.'' In fact, several recent studies using
mouse models revealed that rejection of B16 melanoma can be
accomplished, accompanied by vitiligo-like depigmentation (Hara
et al, 1995b; Overwijk et al, 1999; van Elsas et al, 1999). Also, in this
study, as shown in Table I, the mice with vitiligo showed complete
rejection of B16/IL-12 tumors. This result is compatible with the
clinical observation that the presence of vitiligo-like patches in
melanoma patients indicates a better prognosis. This mouse model
not only demonstrates the depletion of CD4+ T cells as a useful
strategy for cancer gene therapy with IL-12, but also provides a
model for human melanoma-associated vitiligo.
Figure 6. Th2 cytokine gene expressions, but not Th1, were
abolished in the TDLN of B16/IL-12-bearing mice by CD4+ T
cell depletion. We used the reverse transcription±Multiplex PCR system,
by which multiple ampli®ed targets can be detected under the same
conditions. M = PCR markers; P = positive control; lanes 1 and 2 = TDLN
of B16/IL-12-bearing mice with (lane 2) or without (lane 1) CD4+ T cell
depletion on day 7 after tumor injection; lanes 3 and 4 = TDLN of B16/IL-
12-bearing mice with (lane 4) or without (lane 3) CD4+ T cell depletion on
day 21 after tumor injection.
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